Related Experiment Video
Updated: Jun 17, 2026

09:28
Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
Published on: May 12, 2019
Lethal neuroendocrine carcinoma in ulcerative colitis
World Journal of Gastroenterology
|December 10, 2009
Summary
A rapidly lethal neuroendocrine carcinoma developed in a patient with pancolitis, despite prior negative biopsies. This highlights limitations in endoscopic surveillance for aggressive colonic neoplastic lesions.
Area of Science:
- Gastroenterology
- Oncology
- Pathology
Background:
- Longstanding and extensive pancolitis presents a complex clinical scenario.
- Neuroendocrine carcinomas are rare but aggressive malignancies.
- Endoscopic surveillance is crucial for managing chronic inflammatory bowel diseases.
Observation:
- A 48-year-old male with pancolitis developed a high-grade malignant lesion in the ascending colon.
- Previous biopsies from multiple colonic sites showed only inflammatory changes, without dysplasia.
- The lesion was identified as a neuroendocrine carcinoma with a rapid and lethal course.
Findings:
- Neuroendocrine carcinoma can arise in the colon, even after negative surveillance biopsies.
- Aggressive neoplastic lesions may evade detection during standard endoscopic surveillance.
- The biological behavior of some colonic tumors is characterized by rapid progression.
Implications:
- Endoscopic surveillance programs may have limitations in detecting rapidly progressing colonic neoplasms.
- Increased vigilance and potentially advanced diagnostic techniques may be needed for high-risk patients.
- This case underscores the importance of considering rare and aggressive malignancies in patients with chronic colitis.
Related Concept Videos
Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease I: Ulcerative Colitis
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
